原著論文Original Articles

2025年

ワクチン創成グループ 

  1. Autaa G, Papagno L, Nogimori T, Boizard-Moracchini A, Korenkov D, Roy M, Suzuki K, Masuta Y, White E,Llewellyn-Lacey S, Yoshioka Y, Nicoli F, Price DA, Dechanet-Merville J, Yamamoto T, Pellegrin I, Appay V. Aging and inflammation limit the induction of SARS-CoV-2-specific CD8+ T cell responses in severe COVID-19. JCI Insight. 2025 Jan 23;10(4):e180867.
  2. Kawai A, Shimizu T, Tanaka H, Shichinohe S, Anindita J, Hirose M, Kawahara E, Senpuku K, Shimooka M, Quynh Mai LT, Suzuki R, Nogimori T, Yamamoto T, Hirai T, Kato T, Watanabe T, Akita H, Yoshioka Y（コレスポンディングオーサー）. Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits protective immunity against H5N1 influenza virus with reduced adverse reactions. Mol Ther. 2025 Feb 5;33(2):529-547.
  3. Hashimoto S, Hirai T, Ueda K, Kakihara M, Tokunoh N, Ono C, Matsuura Y, Takayama K, Yoshioka Y（コレスポンディングオーサー）. Hypertonic intranasal vaccines gain nasal epithelia access to exert strong immunogenicity. Mucosal Immunol. 2025 Apr 1:S1933-0219(25)00032-7.
  4. Senpuku K, Kunishima Y, Taniguchi K, Ito T, Hirai T, Nakamura T, Kataoka-Nakamura C, Yoshioka Y（コレスポンディングオーサー）. Development and characterization of MRC-5 and Vero cell-adapted enterovirus D68 strains for vaccine production. Vaccine. 2025 Jul 11;60:127314.
  5. Kawaguchi Y, Kimura M, Karaki T, Tanaka H, Ono C, Ishida T, Matsuura Y, Hirai T, Akita H, Shimizu T, Yoshioka Y（コレスポンディングオーサー）. Modulating Immunogenicity and Reactogenicity in mRNA-Lipid Nanoparticle Vaccines through Lipid Component Optimization. ACS Nano. 2025 Aug 5;19(30):27977-28001.

 

ウイルスワクチングループ 

  1. Codon-deoptimized single-round infectious virus for therapeutic and vaccine applications.
    Noguchi T, Miyamori A, Sugimoto T, Miyazato P, Ebina H.
    Sci Rep. 2025 Jul 1;15(1):22033. doi: 10.1038/s41598-025-05643-4.

 

TOP